HEADER TRANSCRIPTION 19-APR-05 1ZEO TITLE CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED TITLE 2 WITH AN ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN (LBD), RESIDUES 203-477; COMPND 5 SYNONYM: PPAR-GAMMA; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PGEX4T2 KEYWDS NUCLEAR RECEPTOR, LIGAND BINDING DOMAIN, LBD, ALPHA HELIX SANDWICH, KEYWDS 2 PPAR-RXR HETERODIMER, TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR G.Q.SHI,J.F.DROPINSKI,B.M.MCKEEVER,A.D.ADAMS,K.L.MACNAUL,A.ELBRECHT, AUTHOR 2 J.P.BERGER,G.ZHOU,T.W.DOEBBER REVDAT 5 03-APR-24 1ZEO 1 REMARK REVDAT 4 14-FEB-24 1ZEO 1 REMARK REVDAT 3 24-JAN-18 1ZEO 1 JRNL REVDAT 2 24-FEB-09 1ZEO 1 VERSN REVDAT 1 25-APR-06 1ZEO 0 JRNL AUTH G.Q.SHI,J.F.DROPINSKI,B.M.MCKEEVER,S.XU,J.W.BECKER, JRNL AUTH 2 J.P.BERGER,K.L.MACNAUL,A.ELBRECHT,G.ZHOU,T.W.DOEBBER,P.WANG, JRNL AUTH 3 Y.-S.CHAO,M.FORREST,J.V.HECK,D.E.MOLLER,B.A.JONES JRNL TITL DESIGN AND SYNTHESIS OF ALPHA-ARYLOXYPHENYLACETIC ACID JRNL TITL 2 DERIVATIVES: A NOVEL CLASS OF PPAR ALPHA/GAMMA DUAL AGONISTS JRNL TITL 3 WITH POTENT ANTIHYPERGLYCEMIC AND LIPID MODULATING ACTIVITY JRNL REF J.MED.CHEM. V. 48 4457 2005 JRNL REFN ISSN 0022-2623 JRNL PMID 15974597 JRNL DOI 10.1021/JM0502135 REMARK 2 REMARK 2 RESOLUTION. 2.50 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNX 2002 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA, REMARK 3 : YIP,DZAKULA) REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.50 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 48.64 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 271300.070 REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000 REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 92.7 REMARK 3 NUMBER OF REFLECTIONS : 21072 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.222 REMARK 3 R VALUE (WORKING SET) : 0.219 REMARK 3 FREE R VALUE : 0.280 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.800 REMARK 3 FREE R VALUE TEST SET COUNT : 1020 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.009 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA. REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL REMARK 3 FREE R VALUE (NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 22674 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 10 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.50 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.59 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 74.50 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1599 REMARK 3 BIN R VALUE (WORKING SET) : 0.3510 REMARK 3 BIN FREE R VALUE : 0.4030 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.40 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 74 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.047 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4069 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 31 REMARK 3 SOLVENT ATOMS : 114 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 51.40 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 57.90 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.49000 REMARK 3 B22 (A**2) : 8.74000 REMARK 3 B33 (A**2) : -8.25000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 9.20000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.34 REMARK 3 ESD FROM SIGMAA (A) : 0.41 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.42 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.50 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.013 REMARK 3 BOND ANGLES (DEGREES) : 1.500 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 20.20 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.000 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 1.540 ; 1.500 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.480 ; 2.000 REMARK 3 SIDE-CHAIN BOND (A**2) : 2.450 ; 2.000 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.540 ; 2.500 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.34 REMARK 3 BSOL : 47.26 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : C1.PAR REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP REMARK 3 TOPOLOGY FILE 2 : C1.TOP REMARK 3 TOPOLOGY FILE 3 : WATER.TOP REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1ZEO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 27-APR-05. REMARK 100 THE DEPOSITION ID IS D_1000032632. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 22-JUN-03 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.5 REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-D REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : OSMIC "PURPLE" CONFOCAL MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22701 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.500 REMARK 200 RESOLUTION RANGE LOW (A) : 48.640 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 200 DATA REDUNDANCY : 5.300 REMARK 200 R MERGE (I) : 0.05200 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 21.1300 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.50 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.60 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.52300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.180 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNX 2002 REMARK 200 STARTING MODEL: SELENOMET PPARGAMMA-LBD COMPLEX REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 56.71 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.86 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.95 M TRISODIUM CITRATE, 0.1 M REMARK 280 TRIS/HCL, 1 MM TCEP, PH 8.5, TEMPERATURE 298K, VAPOR DIFFUSION, REMARK 280 SITTING DROP REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.28650 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 30.72100 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.28650 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 30.72100 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE REMARK 300 THIS ENTRY CONTAINS THE CRYSTALLOGRAPHIC ASYMMETRIC UNIT REMARK 300 WHICH CONSISTS OF 2 CHAINS, A PPARGAMMA HOMODIMER, AN REMARK 300 ARTIFACT OF CRYSTALLIZATION. THIS COULD, HOWEVER, SERVE AS REMARK 300 A MODEL FOR HOW THE BIOLOGICALLY IMPORTANT HETERODIMER, REMARK 300 PPAR-RXR COULD EXIST. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 201 REMARK 465 SER A 202 REMARK 465 GLN A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLY B 201 REMARK 465 SER B 202 REMARK 465 GLN B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 THR B 241 REMARK 465 THR B 242 REMARK 465 LYS B 261 REMARK 465 ILE B 262 REMARK 465 LYS B 263 REMARK 465 PHE B 264 REMARK 465 LYS B 265 REMARK 465 HIS B 266 REMARK 465 ILE B 267 REMARK 465 THR B 268 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 LYS B 275 REMARK 465 THR B 461 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 LEU B 476 REMARK 465 TYR B 477 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU B 207 CG CD OE1 OE2 REMARK 470 SER B 208 OG REMARK 470 THR B 238 OG1 CG2 REMARK 470 LYS B 240 CG CD CE NZ REMARK 470 ASP B 243 CG OD1 OD2 REMARK 470 GLU B 460 CG CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 238 -74.75 -107.81 REMARK 500 LYS A 240 39.74 -75.43 REMARK 500 THR A 242 -56.75 -166.45 REMARK 500 GLU A 259 -0.45 -51.32 REMARK 500 PHE A 360 -11.18 -49.41 REMARK 500 GLU A 427 34.62 -90.89 REMARK 500 SER A 429 -67.81 -24.17 REMARK 500 SER B 355 31.90 -90.74 REMARK 500 ARG B 357 175.89 -41.84 REMARK 500 PHE B 363 -74.82 -53.51 REMARK 500 LEU B 393 43.06 -80.75 REMARK 500 THR B 459 10.87 162.31 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE C01 A 478 REMARK 999 REMARK 999 SEQUENCE REMARK 999 ACCORDING TO AUTHORS, RESIDUES GLY 201 AND SER 202 IN REMARK 999 CHAINS A AND B ARE THE REMNANTS OF A THROMBIN-CLEAVAGE REMARK 999 SITE BETWEEN GLUTATHIONE-S-TRANSFERASE AND PPARGAMMA-LBD DBREF 1ZEO A 203 477 UNP P37231 PPARG_HUMAN 231 505 DBREF 1ZEO B 203 477 UNP P37231 PPARG_HUMAN 231 505 SEQADV 1ZEO GLY A 201 UNP P37231 SEE REMARK 999 SEQADV 1ZEO SER A 202 UNP P37231 SEE REMARK 999 SEQADV 1ZEO GLY B 201 UNP P37231 SEE REMARK 999 SEQADV 1ZEO SER B 202 UNP P37231 SEE REMARK 999 SEQRES 1 A 277 GLY SER GLN LEU ASN PRO GLU SER ALA ASP LEU ARG ALA SEQRES 2 A 277 LEU ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE SEQRES 3 A 277 PRO LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY SEQRES 4 A 277 LYS THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET SEQRES 5 A 277 ASN SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS SEQRES 6 A 277 HIS ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA SEQRES 7 A 277 ILE ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU SEQRES 8 A 277 ALA VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO SEQRES 9 A 277 GLY PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU SEQRES 10 A 277 LEU LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU SEQRES 11 A 277 ALA SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU SEQRES 12 A 277 GLY GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU SEQRES 13 A 277 ARG LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU SEQRES 14 A 277 PHE ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER SEQRES 15 A 277 ASP LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY SEQRES 16 A 277 ASP ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP SEQRES 17 A 277 ILE GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU SEQRES 18 A 277 LYS LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS SEQRES 19 A 277 LEU LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR SEQRES 20 A 277 GLU HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU SEQRES 21 A 277 THR ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR SEQRES 22 A 277 LYS ASP LEU TYR SEQRES 1 B 277 GLY SER GLN LEU ASN PRO GLU SER ALA ASP LEU ARG ALA SEQRES 2 B 277 LEU ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE SEQRES 3 B 277 PRO LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY SEQRES 4 B 277 LYS THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET SEQRES 5 B 277 ASN SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS SEQRES 6 B 277 HIS ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA SEQRES 7 B 277 ILE ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU SEQRES 8 B 277 ALA VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO SEQRES 9 B 277 GLY PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU SEQRES 10 B 277 LEU LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU SEQRES 11 B 277 ALA SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU SEQRES 12 B 277 GLY GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU SEQRES 13 B 277 ARG LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU SEQRES 14 B 277 PHE ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER SEQRES 15 B 277 ASP LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY SEQRES 16 B 277 ASP ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP SEQRES 17 B 277 ILE GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU SEQRES 18 B 277 LYS LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS SEQRES 19 B 277 LEU LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR SEQRES 20 B 277 GLU HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU SEQRES 21 B 277 THR ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR SEQRES 22 B 277 LYS ASP LEU TYR HET C01 A 478 31 HETNAM C01 (2S)-(4-ISOPROPYLPHENYL)[(2-METHYL-3-OXO-5,7-DIPROPYL- HETNAM 2 C01 2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)OXY]ACETATE HETSYN C01 ALPHA-ARYLOXYPHENYLACETIC ACID AGONIST FORMUL 3 C01 C25 H30 N O5 1- FORMUL 4 HOH *114(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 GLY A 258 1 8 HELIX 4 4 GLU A 272 ILE A 303 1 32 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 SER A 332 1 23 HELIX 7 7 ARG A 350 SER A 355 1 6 HELIX 8 8 PRO A 359 PHE A 363 5 5 HELIX 9 9 MET A 364 ASN A 375 1 12 HELIX 10 10 ALA A 376 GLU A 378 5 3 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 GLU A 460 1 31 HELIX 14 14 HIS A 466 LYS A 474 1 9 HELIX 15 15 ALA B 209 PHE B 226 1 18 HELIX 16 16 THR B 229 GLY B 239 1 11 HELIX 17 17 ASP B 251 ASP B 260 1 10 HELIX 18 18 GLU B 276 LYS B 301 1 26 HELIX 19 19 ASP B 310 ALA B 331 1 22 HELIX 20 20 ARG B 350 SER B 355 1 6 HELIX 21 21 PRO B 359 PHE B 363 5 5 HELIX 22 22 MET B 364 ALA B 376 1 13 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 LYS B 458 1 29 HELIX 26 26 HIS B 466 TYR B 473 1 8 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N ILE A 341 O GLY A 346 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 VAL B 339 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 CISPEP 1 LYS A 358 PRO A 359 0 1.43 SITE 1 AC1 12 ALA A 278 PHE A 282 CYS A 285 SER A 289 SITE 2 AC1 12 HIS A 323 ILE A 326 LEU A 330 PHE A 360 SITE 3 AC1 12 PHE A 363 MET A 364 HIS A 449 TYR A 473 CRYST1 92.573 61.442 118.051 90.00 101.72 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010802 0.000000 0.002241 0.00000 SCALE2 0.000000 0.016276 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008651 0.00000